Eisai Company, Ltd. Receives European Medicines Agency Approval to Market Zonegran Monotherapy for Treatment of Epilepsy

July 3, 2012 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, Eisai) announced today that its U.K. subsidiary Eisai Europe Ltd. has received approval from the European Medici…
Read the full story: BioSpace.com Featured News